

For Immediate Release

3 March 2010

ASTERAND PLC
(‘Asterand’ or ‘the Company’)

Notification of Preliminary Results

Date: Tuesday 30 March

Asterand plc (LSE: ATD), (“Asterand” or the “Company”), a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research, will announce its Preliminary Results for the year ended 31 December 2009 on Tuesday 30 March 2010.

The presentation will be given by Martyn Coombs, CEO and John Stchur, CFO. Following this year’s successful acquisition of BioSeek Inc., a pioneer in the application of predictive human biology to drug discovery, there will also be an opportunity to meet Mike Venuti the former BioSeek CEO and now consultant to Asterand.

Analyst meeting:

An analyst briefing will be held at 10:00am on Tuesday 30 March 2010 at the offices of Buchanan Communications, 45 Moorfields, London EC2Y 9AE.

Web cast:

Simultaneously to the analyst briefing at 10:00am, there will be a live audio web cast of the presentation. To connect to the web cast facility, please follow link: <http://mediaserve.buchanan.uk.com/2010/asterand300310/registration.asp> approximately 10 minutes before the start of the briefing (09:50am). This will also be available for replay shortly after the presentation.

- Ends -

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer
John Stchur, Chief Financial Officer

Tel: + 44 (0) 1763 211 600 / + 1 (313) 263-0960
As above

Buchanan Communications

Lisa Baderoon / Mark Court / Jennie Spivey

Tel: +44 (0) 20 7466 5000

Cenkos Securities plc

Stephen Keys / Alex Aylen

Tel: + 44 (0) 20 7397 8924

Daniel Stewart & Company plc

Martin Lampshire

Tel: +44 (0) 20 7776 6550

EDITOR’S NOTES

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one Company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the clinic.